OTC · CIK 0001720893
BTAIQ BioXcel Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 17, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at BioXcel Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Vimal Mehta CEO and President sell | $21k 19,419 shares | -22% | - | |
| 7Weak | Richard I Steinhart Chief Financial Officer sell | $7,427 6,845 shares | -21% | - | |
| 0Weak | Javier Rodriguez See Remarks sell | $7,111 6,560 shares | -20% | - | |
| 0Weak | Frank Yocca Chief Scientific Officer sell | $7,427 6,845 shares | -21% | - | |
| 0Weak | Frank Yocca Chief Scientific Officer sell | $152 430 shares | -1% | - | |
| 0Weak | Javier Rodriguez See Remarks sell | $153 430 shares | -2% | - | |
| 2Weak | Richard I Steinhart Chief Financial Officer sell | $207 577 shares | -3% | - | |
| 5Weak | Vimal Mehta CEO and President sell | $1,131 3,117 shares | -5% | - | |
| 0Weak | Vincent O'Neill See Remarks sell | $58 165 shares | -1% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 16, 2024 | Mehta Vimal Officer | 983 0.00% of outstanding | $340 | Dec 16, 2024 | $1,367 |
| Dec 16, 2024 | Steinhart Richard I Officer | 438 0.00% of outstanding | $154 | Dec 16, 2024 | $4,192 |
| Dec 16, 2024 | Yocca Frank Officer | 430 0.00% of outstanding | $152 | Dec 16, 2024 | $4,191 |
| Dec 16, 2024 | Rodriguez Javier Officer | 430 0.00% of outstanding | $153 | Dec 16, 2024 | $4,014 |
| Dec 16, 2024 | O'Neill Vincent Officer | 165 0.00% of outstanding | $58 | Dec 16, 2024 | $3,151 |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +35 | - | - | 26,210 | Jun 17, 2026 |
| Jun 15, 2026 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +35 | - | - | 26,838 | Jun 17, 2026 |
| Jun 15, 2026 | Vimal Mehta CEO and President | MOption exercise Common Stock | +219 | - | - | 69,817 | Jun 17, 2026 |
| Jun 15, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +35 | - | - | 26,335 | Jun 17, 2026 |
| Jun 15, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 212 | Jun 17, 2026 |
| Jun 15, 2026 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 212 | Jun 17, 2026 |
| Jun 15, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 212 | Jun 17, 2026 |
| Jun 15, 2026 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,313 | Jun 17, 2026 |
| May 4, 2026 | Javier Rodriguez See Remarks | MOption exercise Common Stock10b5-1 | +17,500 | - | - | 33,363 | May 22, 2026 |
| May 4, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +17,500 | - | - | 33,020 | May 22, 2026 |
| May 4, 2026 | Vimal Mehta CEO and President | MOption exercise Common Stock10b5-1 | +49,758 | - | - | 89,017 | May 22, 2026 |
| May 4, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock10b5-1 | +17,500 | - | - | 33,145 | May 22, 2026 |
| May 20, 2026 | Javier Rodriguez See Remarks | SOpen-market sale Common Stock10b5-1 | -6,560 | $1.08 | $7,111 | 26,803 | May 22, 2026 |
| May 20, 2026 | Vimal Mehta CEO and President | SOpen-market sale Common Stock10b5-1 | -19,419 | $1.09 | $21k | 69,598 | May 22, 2026 |
| May 20, 2026 | Richard I Steinhart Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -6,845 | $1.09 | $7,427 | 26,300 | May 22, 2026 |
| May 20, 2026 | Frank Yocca Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,845 | $1.09 | $7,427 | 26,175 | May 22, 2026 |
| May 4, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -17,500 | $0.00 | $0 | 52,500 | May 22, 2026 |
| May 4, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -17,500 | $0.00 | $0 | 52,500 | May 22, 2026 |
| May 4, 2026 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative10b5-1 | -17,500 | $0.00 | $0 | 52,500 | May 22, 2026 |
| May 4, 2026 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative10b5-1 | -49,758 | $0.00 | $0 | 149,274 | May 22, 2026 |
| May 1, 2026 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +9,000 | - | - | 15,863 | May 7, 2026 |
| May 1, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +9,000 | - | - | 15,520 | May 7, 2026 |
| May 1, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +9,000 | - | - | 15,645 | May 7, 2026 |
| May 1, 2026 | Vimal Mehta CEO and President | MOption exercise Common Stock | +18,000 | - | - | 39,259 | May 7, 2026 |
| May 1, 2026 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -9,000 | $0.00 | $0 | 0 | May 7, 2026 |
| May 1, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -9,000 | $0.00 | $0 | 0 | May 7, 2026 |
| May 1, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -9,000 | $0.00 | $0 | 0 | May 7, 2026 |
| May 1, 2026 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -18,000 | $0.00 | $0 | 0 | May 7, 2026 |
| Mar 14, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +33 | - | - | 6,485 | Mar 16, 2026 |
| Mar 14, 2026 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +33 | - | - | 6,828 | Mar 16, 2026 |
| Mar 14, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +33 | - | - | 6,610 | Mar 16, 2026 |
| Mar 14, 2026 | Vimal Mehta CEO and President | MOption exercise Common Stock | +164 | - | - | 21,040 | Mar 16, 2026 |
| Mar 15, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +35 | - | - | 6,645 | Mar 16, 2026 |
| Mar 15, 2026 | Vimal Mehta CEO and President | MOption exercise Common Stock | +219 | - | - | 21,259 | Mar 16, 2026 |
| Mar 15, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +35 | - | - | 6,520 | Mar 16, 2026 |
| Mar 15, 2026 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +35 | - | - | 6,863 | Mar 16, 2026 |
| Mar 14, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 97 | Mar 16, 2026 |
| Mar 14, 2026 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 97 | Mar 16, 2026 |
| Mar 14, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 97 | Mar 16, 2026 |
| Mar 15, 2026 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 247 | Mar 16, 2026 |
| Mar 15, 2026 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 247 | Mar 16, 2026 |
| Mar 15, 2026 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 247 | Mar 16, 2026 |
| Mar 14, 2026 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -164 | $0.00 | $0 | 488 | Mar 16, 2026 |
| Mar 15, 2026 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,532 | Mar 16, 2026 |
| Jan 9, 2026 | David J. Mack director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 9, 2026 | June Bray director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 9, 2026 | Michael Patrick Miller director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 9, 2026 | Michal Votruba director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 9, 2026 | Peter Mueller director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 9, 2026 | Rajiv Patni director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 9, 2026 | Sandeep Laumas director | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jan 12, 2026 |
| Jan 1, 2026 | Javier Rodriguez See Remarks | AGrant or award Restricted Stock Unitsderivative | +70,000 | $0.00 | $0 | 70,282 | Jan 5, 2026 |
| Jan 1, 2026 | Vimal Mehta CEO and President | AGrant or award Restricted Stock Unitsderivative | +199,032 | $0.00 | $0 | 200,783 | Jan 5, 2026 |
| Jan 1, 2026 | Richard I Steinhart Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +70,000 | $0.00 | $0 | 70,282 | Jan 5, 2026 |
| Jan 1, 2026 | Frank Yocca Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +70,000 | $0.00 | $0 | 70,282 | Jan 5, 2026 |
| Dec 14, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +33 | - | - | 6,417 | Dec 15, 2025 |
| Dec 14, 2025 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +33 | - | - | 6,760 | Dec 15, 2025 |
| Dec 14, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +33 | - | - | 6,542 | Dec 15, 2025 |
| Dec 14, 2025 | Vimal Mehta CEO and President | MOption exercise Common Stock | +164 | - | - | 20,657 | Dec 15, 2025 |
| Dec 15, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +35 | - | - | 6,452 | Dec 15, 2025 |
| Dec 15, 2025 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +35 | - | - | 6,795 | Dec 15, 2025 |
| Dec 15, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +35 | - | - | 6,577 | Dec 15, 2025 |
| Dec 15, 2025 | Vimal Mehta CEO and President | MOption exercise Common Stock | +219 | - | - | 20,876 | Dec 15, 2025 |
| Dec 14, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 130 | Dec 15, 2025 |
| Dec 14, 2025 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 130 | Dec 15, 2025 |
| Dec 14, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 130 | Dec 15, 2025 |
| Dec 15, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 282 | Dec 15, 2025 |
| Dec 15, 2025 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 282 | Dec 15, 2025 |
| Dec 15, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 282 | Dec 15, 2025 |
| Dec 14, 2025 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -164 | $0.00 | $0 | 652 | Dec 15, 2025 |
| Dec 15, 2025 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,751 | Dec 15, 2025 |
| Oct 31, 2025 | David J. Mack director | MOption exercise Common Stock | +1,694 | - | - | 20,317 | Nov 3, 2025 |
| Oct 31, 2025 | David J. Mack director | MOption exercise Restricted Stock Unitsderivative | -1,694 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Sep 30, 2025 | David J. Mack director | MOption exercise Common Stock | +1,694 | - | - | 18,623 | Oct 1, 2025 |
| Sep 30, 2025 | David J. Mack director | MOption exercise Restricted Stock Unitsderivative | -1,694 | $0.00 | $0 | 1,694 | Oct 1, 2025 |
| Sep 14, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +33 | - | - | 6,349 | Sep 16, 2025 |
| Sep 14, 2025 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +33 | - | - | 6,692 | Sep 16, 2025 |
| Sep 14, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +33 | - | - | 6,474 | Sep 16, 2025 |
| Sep 14, 2025 | Vimal Mehta CEO and President | MOption exercise Common Stock | +163 | - | - | 20,274 | Sep 16, 2025 |
| Sep 15, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Common Stock | +35 | - | - | 6,384 | Sep 16, 2025 |
| Sep 15, 2025 | Javier Rodriguez See Remarks | MOption exercise Common Stock | +35 | - | - | 6,727 | Sep 16, 2025 |
| Sep 15, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Common Stock | +35 | - | - | 6,509 | Sep 16, 2025 |
| Sep 15, 2025 | Vimal Mehta CEO and President | MOption exercise Common Stock | +219 | - | - | 20,493 | Sep 16, 2025 |
| Sep 14, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 163 | Sep 16, 2025 |
| Sep 14, 2025 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 163 | Sep 16, 2025 |
| Sep 14, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 163 | Sep 16, 2025 |
| Sep 15, 2025 | Frank Yocca Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 317 | Sep 16, 2025 |
| Sep 15, 2025 | Javier Rodriguez See Remarks | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 317 | Sep 16, 2025 |
| Sep 15, 2025 | Richard I Steinhart Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 317 | Sep 16, 2025 |
| Sep 14, 2025 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -163 | $0.00 | $0 | 816 | Sep 16, 2025 |
| Sep 15, 2025 | Vimal Mehta CEO and President | MOption exercise Restricted Stock Unitsderivative | -219 | $0.00 | $0 | 1,970 | Sep 16, 2025 |
| Aug 31, 2025 | David J. Mack director | MOption exercise Common Stock | +1,693 | - | - | 16,930 | Sep 2, 2025 |
| Aug 31, 2025 | David J. Mack director | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 3,387 | Sep 2, 2025 |
| Aug 1, 2025 | Vimal Mehta CEO and President | AGrant or award Restricted Stock Unitsderivative | +18,000 | $0.00 | $0 | 18,000 | Aug 5, 2025 |
| Aug 1, 2025 | Frank Yocca Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +9,000 | $0.00 | $0 | 9,000 | Aug 5, 2025 |
| Aug 1, 2025 | Javier Rodriguez See Remarks | AGrant or award Restricted Stock Unitsderivative | +9,000 | $0.00 | $0 | 9,000 | Aug 5, 2025 |
| Aug 1, 2025 | Richard I Steinhart Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +9,000 | $0.00 | $0 | 9,000 | Aug 5, 2025 |
| Jul 31, 2025 | David J. Mack director | MOption exercise Common Stock | +1,693 | - | - | 15,237 | Jul 31, 2025 |
| Jul 31, 2025 | David J. Mack director | MOption exercise Restricted Stock Unitsderivative | -1,693 | $0.00 | $0 | 5,080 | Jul 31, 2025 |
| Jul 22, 2025 | Javier Rodriguez See Remarks | AGrant or award Common Stock | +4,375 | - | - | 6,034 | Jul 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- June Braydirector
- Sandeep Laumascfo, officer, director
- David J. Mackdirector
- Michael Patrick Millerdirector
- Peter Muellerdirector
- Vimal MehtaCEO and President
- Vincent O'NeillSee Remarks
- Rajiv Patnidirector, officer
- Javier RodriguezSee Remarks
- Richard I SteinhartChief Financial Officer
- Michal Votrubadirector
- Frank YoccaChief Scientific Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.